Login / Signup

Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma.

Taku KikuchiNobuhiro TsukadaKodai KunisadaMoe Nomura-YogoYuki OdaKota SatoTomomi TakeiMizuki OguraYu AbeKenshi SuzukiTadao Ishida
Published in: Acta haematologica (2024)
Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.
Keyphrases
  • multiple myeloma
  • mesenchymal stem cells
  • cell therapy
  • smoking cessation